Current Drug Targets - Cardiovascular & Hematological Disorders

Thrombin Activable Fibrinolysis Inhibitor (TAFI): Molecular Genetics of an Emerging Potential Risk Factor for Thrombotic Disorders
pp. 59-74(17)
Authors: Boffa M.B.; Nesheim M.E.; Koschinsky M.L.

Contributory Role of Matrix Metalloproteinases in Cardiovascular Remodeling
pp. 75-91(19)
Authors: Gunasinghe S.K.; Ikonomidis J.; Spinale F.G.

Apolipoprotein E: Possible Therapeutic Target for Atherosclerosis
pp. 93-106(16)
Authors: Bocksch L.; Stephens T.; Lucas A.; Singh B.

Reduction and Prevention of the Cardiovascular Sequelae of the Insulin Resistance Syndrome
pp. 107-120(15)
Author: Russell J.C.